# Repertoire Genesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/repertoire-genesis

- Industry: Biotechnology
- Headquarters: Ibaraki-shi, Japan
- Website: www.repertoire.co.jp
- Total disclosed funding: $9.2M
- Latest round: Series C (Aug 31, 2017)
- Investors on record: 2

## About

Based in Tokyo, Japan, established in 2014, Repertoire Genesis Inc. is implementing a new treatment methodology using immune diversity analysis technology. By analyzing immunity's diversity, the mechanism of intractable diseases, which was not understood to date, can be clarified. As a consequence, efficient drug development can take place. Additionally, individually tailored treatment selection is expected. A business centered on technology will be developed to analyze immunity's diversity. Repertoire Genesis Inc. is working on the development of new treatments and diagnostic methods for patients suffering from diseases worldwide. 
A platform provided by a conventional bio-venture company generally targets a research institute (academia) or a pharmaceutical company for a specific task. For example, the task of discovering drug candidates is targeted to a pharmaceutical company. Repertoire Genesis Inc.'s platform can provide individualized flexible services for different tasks. It can target multiple institutions such as universities and other research institutions, pharmaceutical companies, diagnostic drug companies, and medical service providers.
The company plans on promoting efficient medical care by performing immune diversity analysis. Its analysis of immune cells, abnormalities of living organisms affecting them and their coexisting bacteria is based on studies at a gene level using TCR / BCR repertoire analysis, neoepitope analysis, 16S rRNA flora analysis. This way, the company can provide clear information on what was unknown so far to the medical scene. This approach can be used in several fields such as blood tumors, tumor immunity, transplantation immunity, autoimmune diseases, infectious diseases, fundamental immunity research.
Since our establishment in 2014, the company has accumulated significant experience in providing services to research institutes such as universities. In recent years, the company has received orders of medium to large projects from pharmaceutical companies following our achievements in academia.
Cell therapy is a methodology of treating diseases by using one's own cells or cells from others. It is attracting attention as a challenging technology to treat diseases difficult to cure by conventional treatment methods. It is well known for CAR-T cell therapy, which has been used in the USA and Europe. However, current cell therapy is limited by the expensive treatment costs, efficacy, and safety. These issues represent our focus. The company is working on developing novel technologies and other solutions to overcome these problems. From now on, with the use of these technologies, the company plans on focusing on research, development, and commercialization. Their aim is to develop novel cell therapy which is cheaper, effective, and safe.

## Funding rounds

- Series C, Aug 31, 2017, $2.7M — University of Tokyo Edge Capital Partners, Beyond Next Ventures
- Series B, Jul 27, 2016, $4.8M — University of Tokyo Edge Capital Partners, Beyond Next Ventures
- Series A, Nov 21, 2014, $1.7M — University of Tokyo Edge Capital Partners

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B, Series C
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series B, Series C